Oncology

Can Biosimilars Be Switched?

December 12th 2019

Are Biosimilars and Biologics Similar?

December 12th 2019

What Are Biosimilars?

December 12th 2019

Available Oncology Biosimilars and Their Efficacy

December 12th 2019

Biosimilar Trastuzumab, Ogivri, and Its Reference in Combination With Pertuzumab Show Similar Activity

December 10th 2019

By The Center for Biosimilars Staff

While biosimilars approved by regulators have been shown to have no clinically meaningful differences from their reference products, this week, during the San Antonio Breast Cancer Symposium, held in San Antonio, Texas, researchers will report reassuring data for biosimilar trastuzumab, Ogivri, showing that the combination of the biosimilar with pertuzumab is highly similar to the combination of the reference drug with pertuzumab.

Slower Price Growth, Use of Generics Balance Higher Spending on Cancer, Autoimmune Drugs

December 10th 2019

By Allison Inserro

Increased spending on new oncology and autoimmune drugs was partially offset by a decline in price growth and the continued increase in the use of generic drugs, according to a recent report from CMS about national healthcare spending in 2018.

At ASH, Data on Truxima Underscore the Biosimilar's Safety and Efficacy

December 9th 2019

By Kelly Davio

Celltrion and Teva’s biosimilar rituximab, CT-P10, Truxima, recently launched in the United States. The product is the first rituximab biosimilar to become available to US patients, and during this week’s 61st meeting of the American Society of Hematology (ASH), 2 research teams presented data that highlight the biosimilar’s safety and efficacy in patients with lymphoma.

Lee Schwartzberg, MD, FACP: Lessons Learned From Supportive Care Biosimilars

December 9th 2019

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses what oncologists have learned from experience with supportive care that can be applied to adopting anticancer biosimilars.

NeuClone's Proposed Trastuzumab Biosimilar Met Primary, Secondary End Points in Phase 1 Trial

December 6th 2019

By Kelly Davio

NeuClone did not specify whether it intends to move to a phase 3 clinical trial for the biosimilar. In fact, in its statement on the phase 1 results, the company noted that phase 3 trials are not required to achieve regulatory clearance.

Biocad's Rituximab Biosimilar Shows Safety, Efficacy in NHL, RA

December 4th 2019

By The Center for Biosimilars Staff

Drug developer Biocad received approval for its rituximab biosimilar, BCD-020 (Acellbia) in Russia in 2014, and since that time, the drug has been launched in Russia and in multiple other markets around the world. While Biocad has not specified whether it plans to pursue regulatory approval for the biosimilar in the European Union, the company has announced ambitions to enter the EU market with some of its products, and researchers have published new data for the biosimilar in both oncology and rheumatology indications.